Clinical trials Brief October 29, 2026, 10:00 AM ET

Boehringer Ingelheim posts results of 1-yr Tiotropium/Salmeterol study in COPD

Results for the 220-participant, Phase 3, randomized, triple-masked study were posted on October 29, 2026. The study compared FDC tiotropium/salmeterol with single agents and assessed FEV1, dyspnoea, health status and exacerbations.

Primary source

ClinicalTrials.gov results record, October 29, 2026

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Read the source: Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD) clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation